Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study

• প্রধান লেখক: Nestor Szerman (লেখক), Ignacio Basurte-Villamor (লেখক), Pablo Vega (লেখক), Jose Martinez-Raga (লেখক), Carlos Parro-Torres (লেখক), Julia Cambra Almerge (লেখক), Lara Grau-López (লেখক), Mario De Matteis (লেখক), Francisco Arias (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Adis, Springer Healthcare, 2020-02-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone...